Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
1. Enliven Therapeutics will present five posters at AACR Annual Meeting 2025.
2. ELVN-002 shows potential with HER2-targeted therapies, possibly increasing competitive advantage.
3. ELVN-001 targets chronic myeloid leukemia and demonstrates promising combination therapies.
4. Posters detail innovative drug development for challenging cancer types.
5. The annual meeting offers high visibility and networking opportunities for ELVN.
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
Poster Presentation Details
Abstract 4712 – ELVN-002
A potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates
Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model to predict anti-chronic myeloid leukemia (CML) effects of tyrosine kinase inhibitors
Session: Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics
Location: Poster Section 20
Abstract LB295 – ELV-3111
A type 1 pan-RAF inhibitor, that safely combines with MEK inhibitors for enhanced anti-tumor activity in NRAS and BRAF mutant cancers including the most common mechanisms of BRAF inhibitor clinical resistance
Session: Drug Resistance in Molecular Targeted Therapies 3
Location: Poster Section 17
Abstracts are currently available on the AACR website. Following the presentations, copies will be available on the "Program Presentations & Publications" section of the Company's website at www.enliventherapeutics.com.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.
